Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression

Pathology. 2019 Oct;51(6):655-657. doi: 10.1016/j.pathol.2019.07.004. Epub 2019 Aug 27.

¹ Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; ONTrac at Peter Mac Victorian Adolescent and Young Adult Cancer Service, Melbourne, Vic, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Vic, Australia. Electronic address: jeremy.lewin@petermac.org.
² Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Vic, Australia.
³ Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
⁴ Department of Anatomical Pathology, PathWest, QEII Medical Centre, Nedlands, WA, Australia; School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, WA, Australia.

No abstract available

Publication types